US EditionPublished • loading... • Updated
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis - Pipelinereview
Summary by Pipelinereview
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis - Pipelinereview
BRIDGEWATER, NJ, USA and BENGALURU, India I March 7, 2025 I Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, randomized, double-blind, parallel group, multicenter study comparing Yesintek™ (Biocon Biologics’ biosimilar to Ustekinumab, called YESINTEK) with reference product Stelara (Ustekinumab) in…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
